Lunacalcipol

Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT) [1].

Product Specifications

CAS Number

[250384-82-8]

Product Name Alternative

CTA-018

UNSPSC

12352100

Target

Cytochrome P450; VD/VDR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Endocrinology; Others

Assay Protocol

https://www.medchemexpress.com/lunacalcipol.html

Smiles

C[C@@]12[C@](CC=C2[C@H](C)C/C=C/S(C(C)(C)C)(=O)=O)([H])/C(CCC1)=C/C=C3C([C@H](C[C@@H](C\3)O)O)=C

Molecular Formula

C28H42O4S

Molecular Weight

474.70

References & Citations

[1]Nagamani S, et al. A theoretical insight to understand the molecular mechanism of dual target ligand CTA-018 in the chronic kidney disease pathogenesis[J]. PloS one, 2018, 13 (10) : e0203194.